Treatment of inflammatory bowel disease by leukocytapheresis

Simple item page
dc.contributor.authorGerçeker E.
dc.contributor.authorYüceyar H.
dc.contributor.authorKasap E.
dc.contributor.authorDemirci U.
dc.contributor.authorEkti B.C.
dc.contributor.authorAydoğdu İ.
dc.contributor.authorMiskioğlu M.
dc.date.accessioned2024-07-22T08:10:39Z
dc.date.available2024-07-22T08:10:39Z
dc.date.issued2017
dc.description.abstractStudies about leukocytapheresis have emerged with the need of search for alternatives to conventional treatment in inflammatory bowel diseases (IBD). Leukocytapheresis is a novel non-pharmacologic approach for active ulcerative colitis (UC) and Crohn's disease (CD), in which leukocytes are mechanically removed from the circulatory system. Patients with active IBD treated with leukocytapheresis using a Cellsorba E column between 2012 and 2015, were enrolled in Turkey. In our experience, the results of leukocytapheresis therapy in 6 patients with CD and 20 patients with active UC were overviewed. Leukocytapheresis (10 sessions for remission induction therapy, 6 sessions for maintenance therapy) was applied to the patients with their concomitant medications. Intensive leukocytapheresis (≥4 leukocytapheresis sessions within the first 2 weeks) was used in 30% patients with active severe UC. The overall clinical remission rate in patients with UC was 80%, and the mucosal healing rate was 65%. Patients were followed for an average of 24 months. It was observed that clinical remission has continued in 65% of patients with UC. Mild relapse was observed in 3 patients with UC during follow up period. In 5 patients with CD significant clinical remission was achieved except only one patient. Surgical needs were disappeared in 3 patients with obstructive type Crohn's disease. Adverse events were seen in only 4.3% of 416 sessions. Any concomitant medications did not increase the incidence of adverse events. Our results indicate that leukocytapheresis is efficacious in improving remission rates with excellent tolerability and safety in patients with IBD. © 2017 Elsevier Ltd
dc.identifier.DOI-ID10.1016/j.transci.2017.03.016
dc.identifier.issn14730502
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15332
dc.language.isoEnglish
dc.publisherElsevier Ltd
dc.subjectAdult
dc.subjectFemale
dc.subjectHumans
dc.subjectInflammatory Bowel Diseases
dc.subjectLeukapheresis
dc.subjectMale
dc.subjectadalimumab
dc.subjectazathioprine
dc.subjectganciclovir
dc.subjectmesalazine
dc.subjectsteroid
dc.subjectadult
dc.subjectArticle
dc.subjectclinical article
dc.subjectclinical outcome
dc.subjectcolitis
dc.subjectcolonoscopy
dc.subjectCrohn disease
dc.subjectcytapheresis
dc.subjectcytomegalovirus infection
dc.subjectdisease severity
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjecthuman tissue
dc.subjecthypotension
dc.subjectinflammatory bowel disease
dc.subjectintestine mucosa
dc.subjectleukocytapheresis
dc.subjectlow drug dose
dc.subjectmaintenance therapy
dc.subjectmale
dc.subjectrelapse
dc.subjectremission
dc.subjectulcerative colitis
dc.subjectwound healing
dc.subjectinflammatory bowel disease
dc.subjectleukapheresis
dc.subjectpathology
dc.subjectprocedures
dc.titleTreatment of inflammatory bowel disease by leukocytapheresis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu